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Abstract. Breast cancer is the most frequent cancer among women and the leading cause of death 
among  middle-aged  women.  Early  detection  by  mammography  screening  and  improvement  of 
therapeutic options have increased breast cancer sur
effects of cancer treatment become increasingly  important. In particular, patients treated with 
adjuvant chemotherapy regimens, commonly including alkylating agents and anthracyclines, are 
at increased risk of developing leukemia, further enhanced by the use of radiotherapy. In the last 
few years also the use of growth factors seems to increase the risk of secondary leukemia. The 
purpose of this review is to update epidemiology of therapy
in breast cancer patients.
Epidemiology  and  Mortality  Of  Breast  Cancer
Excluding skin cancers, breast cancer (BC) is the most 
common  malignancy  among  women  in  developed 
country,  accounting  for  about  one-third  of  all  new 
cancer cases in the United States (n= 230480; 30%), 
and  it  is  the  second  leading  cause  of  cancer  death 
among  women.  Despite  the  high    incidence,  the 
mortality rate is low (15%), and, as a result of early 
diagnosis and the increasing use of adjuvant therapy, 
there  is  a  rising  number  of  long-term  survivors.
Several studies have reported an increased 
acute myeloid leukemia (AML) after treatment of BC, 
with  evidence  of  a  dose-intensity  relationship.  It  is 
estimated  that  1  every  20  patients  will  develop  a 
secondary  non-breast  cancer  after  10  years,  which 
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Breast cancer is the most frequent cancer among women and the leading cause of death 
aged  women.  Early  detection  by  mammography  screening  and  improvement  of 
therapeutic options have increased breast cancer survival rates, with the consequence that late side 
effects of cancer treatment become increasingly  important. In particular, patients treated with 
adjuvant chemotherapy regimens, commonly including alkylating agents and anthracyclines, are 
of developing leukemia, further enhanced by the use of radiotherapy. In the last 
few years also the use of growth factors seems to increase the risk of secondary leukemia. The 
purpose of this review is to update epidemiology of therapy-related myeloid neop
nd  Mortality  Of  Breast  Cancer. 
Excluding skin cancers, breast cancer (BC) is the most 
women  in  developed 
third  of  all  new 
= 230480; 30%), 
and  it  is  the  second  leading  cause  of  cancer  death 
among  women.  Despite  the  high    incidence,  the 
a result of early 
diagnosis and the increasing use of adjuvant therapy, 
term  survivors.
1,2
Several studies have reported an increased incidence of 
acute myeloid leukemia (AML) after treatment of BC, 
intensity  relationship.  It  is 
estimated  that  1  every  20  patients  will  develop  a 
breast  cancer  after  10  years,  which 
corresponds to  a  22%  increase  of  relative  risk, 
particularly  for  secondary  AML  and  myelodisplastic 
syndromes (MDS).
3-5
Differences Between  Therapy
Secondary  Acute  Myeloid  Leukemia. 
related  acute  myeloid  leukemia  or  myelodisplastic 
syndromes (t-AML/MDS)  are  collectively  known  as 
therapy-related  myeloid  neoplasms  (t
among  “Acute  myeloid  leukemias 
precursor neoplasms” in the 2008 WHO classification.
The term “therapy-related” leukemia is descriptive and 
based  on  patient’s  history  of  exposure  to  cytotoxic 
agents.  The  latency  between  primary  diagnosis  and 
therapy-related  disease  ranges  fr
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aged  women.  Early  detection  by  mammography  screening  and  improvement  of 
vival rates, with the consequence that late side 
effects of cancer treatment become increasingly  important. In particular, patients treated with 
adjuvant chemotherapy regimens, commonly including alkylating agents and anthracyclines, are 
of developing leukemia, further enhanced by the use of radiotherapy. In the last 
few years also the use of growth factors seems to increase the risk of secondary leukemia. The 
related myeloid neoplasms occurring 
to  a  22%  increase  of  relative  risk, 
secondary  AML  and  myelodisplastic 
Between  Therapy-Related  and 
econdary  Acute  Myeloid  Leukemia.  Therapy-
related  acute  myeloid  leukemia  or  myelodisplastic 
AML/MDS)  are  collectively  known  as 
related  myeloid  neoplasms  (t-MN),  included 
among  “Acute  myeloid  leukemias  and  related 
precursor neoplasms” in the 2008 WHO classification.
6
related” leukemia is descriptive and 
based  on  patient’s  history  of  exposure  to  cytotoxic 
agents.  The  latency  between  primary  diagnosis  and 
related  disease  ranges  from  few  months  to Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
several  years,  with  a  median  of  about  two  years, 
depending in part on the cumulative dose and/or the 
dose-intensity of the preceeding cytotoxic therapy, as 
well  on  the  exposure  to  specific  agents.
7-9 Besides 
"therapy-related" forms, there are AML/MDS defined 
as  “second  malignancy”  arising  as  a  second  cancer 
after a previous diagnosis of a neoplasm treated with 
surgery alone. 
Currently  accounting  for  10-20%  of  all  cases  of 
AML,
10 the outcome of patients with t-AML compared 
with that of de novo AML, has been historically poor, 
with a higher frequency of poor-risk cytogenetics and 
shorter  survival  times.
11-13 Patients  are  often  poor 
candidates  for  intensive  AML  therapy  because  of 
protracted damage from prior cytotoxic therapy and, in 
some  cases,  for  the  persistence  of  their  primary 
disorder.   Moreover, t-AML is  relatively  resistant to 
conventional therapies used for de novo leukemias.
Pathogenesis  of  t-MN  After  Breast  Cancer. 
Chemotherapy  with  DNA-targeted  antiproliferative 
drugs  in  the  adjuvant  setting  has  contributed  to 
significant  progress  in  the  management  of  BC, 
substantially  increasing  the  number  of  long-term 
survivors. As the risk of developing cancer increases 
with  age,  longer  survival  is  associated  with  an 
increased  probability  of  new cancer  occurrence, 
particularly  of  developing  t-AML/MDS.  In  the 
majority of cases they are represented by AML, but a 
secondary  acute  lymphoblastic  leukemia  is  possible, 
although less common.
14,15 In the last decades the type 
of solid tumors preceding t-MN has changed: among 
3026 newly diagnosed AML, there were 142 of 200 t-
MN with a previous history of solid cancer, with BC 
representing the most common neoplasm (52%). The 
median  latency  between  diagnosis  of  primary 
malignancy  and  the  occurrence  of  t-AML  was  four 
years, and was shorter in patients younger at the time 
of  primary  malignancy  diagnosis  or  treated  with 
anthracyclines and/or topoisomerase-II inhibitors.
10
Several studies have reported an increased risk for 
AML  in  BC  patients  treated  with  adjuvant  therapy 
(Table  1  and  Table  2),  but  it  remains  unclear if  t-
AML represents a truly stochastic event or if individual 
susceptibility plays  a  role.
16 Already  40  years  ago 
Metcalf et al demonstrated a correlation between acute 
leukemia  and  BC  and  hypothesized  common  risk 
factors for both diseases.
17 This observation has been 
confirmed  in  various  series  of  patients  showing  that 
there  is  an  increased  risk  of  developing  AML  in 
patients with BC treated with surgery alone, or with 
family history of BC, so that individual susceptibility 
for  development  of  multiple  tumors  and  a  possible 
association  between  the  two  diseases  must  be 
hypothesized.
18-20 It  is  currently  difficult  to  define 
individual susceptibility, because only few pathological 
conditions,  above  all  constitutional  and  genetically 
determined, are known to predispose to leukemia. The 
interaction  between  the  genotoxic  effects  of 
chemotherapy or ionizing radiation and the “host” is 
influenced, among others, by genetic polymorphism in 
drug  metabolism  and  DNA  repair  processes,  which 
may increase individual susceptibility to these agents. 
Furthermore, the observation of secondary leukemias 
in patients who did not receive chemio- or radiotherapy 
for  their  primary  tumor  suggests  the  existence of  a 
common  predisposing  condition,  possibly  a  general 
cancer susceptibility. 
A  population-based  study  from  a  French  Cancer 
Registry  evaluated  the  risk  of  developing  a  new 
primary invasive cancer during the first five years of 
follow up for 14353 cancer patients (breast, colorectal 
and  prostate  cancer),  comparing  with  the  expected 
numbers, based on primary cancer incidence rate using 
the  standardized  incidence  ratio  (SIR).  Overall,  690 
second cancers were registered, including 15 AML. In 
particular,  among  5663  women  treated  for  BC,  10 
developed t-AML, which results into a greater risk than 
the general population (SIR=8.26, p<0.05).
21 AML risk 
after a prior BC was also examined in an Australian 
retrospective population-based study and this risk was 
compared to that of survivors after a prior diagnosis of 
hematological  malignancies  and  other  cancers 
combined. Among 183123 women diagnosed with BC, 
158  (0.09%) subsequently  developed AML,  with the 
result that women with a prior diagnosis of BC were 
2.6 times more likely to develop AML compared to the 
general  female  population  (p<0.001).  Although  the 
incidence of AML rose sharply with age in all cohorts, 
the age-specific relative risk was highest in the 30-49 
age groups and decreased with increasing age. An age-
dependent risk of a subsequent diagnosis of AML was 
confirmed in women <50 years and in the range 50-64 
years with previous BC, but not in those older than 65 
years,  if  compared  with  the  expected  incidence  of 
AML. A similar age-dependent pattern was observed 
for  second  BC  and  ovarian  cancers;  this  association 
may be explained by either chemotherapy exposure or 
an  interaction  between  therapy  and  genetic 
predisposition.
22 On the other hand, Patt et al evaluated 
the risk of AML in older women treated with modern 
schedules,  demonstrating  that  while  older  women 
treated  with  adjuvant  chemotherapy  had  more  than 
50% increased risk of AML, the absolute increase in 
risk  at  10  years  was  low  (1.8%  in  treated  patients 
versus 1.2%  among  patients  who  did  not  received 
chemotherapy).
23
Role  of  Adjuvant  Chemotherapy.  Adjuvant 
chemotherapy for BC has undergone major changes, Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
Table 1. Risk of therapy-related myeloid neoplasms in breast cancer patients receiving adjuvant chemotherapy with alkylating agents.
Reference Breast cancer 
patients (n) Therapy t-MN (n) Cumulative risk (%)
Valagussa et al, 1994 [36] 2465 CMF 3 0.23 (at 15 y)
Bernard-Marty et al, 2002 [34] 255 CMF 0 0 (at 5 y)
Praga et al, 2005 [37] 1427 CMF 1 0.07 (at 8 y)
Ejlertsen et al, 2007 [24] 629 CMF 2 nr
Hershman et al, 2007 [40] 3330 Cyclophosphamide-based 
regimens 40 1.20
CMF: cyclophosphamide, methotrexate, and fluorouracil; nr: not reported.
expanding  from  node-positive  women  to  lower  risk 
patients.  Anthracycline-containing  regimens  have 
shown superiority in comparison to cyclophosphamide, 
methotrexate and 5-fluorouracil (CMF). Incorporation 
of  taxanes  (paclitaxel  and  docetaxel)  into 
anthracyclines-based  schedules  yielded  an  additional 
benefit in both disease-free survival (DFS) and overall 
survival  (OS)  in  most  studies,  and  dose-dense  drug 
administration have shown to be more effective than 
the  conventional  dosing  schedule.
24-28 These  novel 
therapeutic strategies have resulted into a considerable 
improvement of BC survival, but also into an increased 
t-AML/MDS rate.
29-35 Of note, it must be kept in mind 
that a under-reported incidence of overall t-MN in the 
different registries is likely, and difficult to accurately 
estimate, because of an inadequate coding, not specific 
for t-AML or t-MDS. 
Alkylating agents. In the past, alkylating agents were 
the  class  of  antineoplastic  drugs  unequivocally 
associated  with  t-MN  (Table  1).  The  antineoplastic 
activity  of  these  drugs  is  related  to  their  ability  to 
damage  DNA  by  methylation  or  DNA  inter-strand 
crosslinks formation,  interfering  with  normal  DNA 
replication.  Alkylating  agent-related  AML  typically 
develops  after  an  average  latency  of  5-7  years,  and 
overt leukemia is often (up to 70% of cases) proceeded 
by a dysplastic phase.
9,11 Fisher et al reported that the 
10-year  cumulative  risk  of  AML  was  increased  in 
patients treated with surgery followed by melphalan-
based  chemotherapy  compared  to  those  treated  with 
surgery alone (1.29% versus 0.27%, respectively).
30 In 
the  following  years  the  leukemogenic  potential  of 
cyclophosphamide has  emerged.  Several  studies 
indicated  that  the  risk  for  developing  AML/MDS 
among  patients  with  early-stage  BC  treated  with 
adjuvant  chemotherapy  containing  standard  dose 
cyclophosphamide  is  higher  than  that  of  the  general 
population,
31,36 although the risk of developing t-MN in 
patients treated with melphalan is 10 times higher than 
that of patients who received cyclophosphamide.
32 In 
fact  the  risk  for  AML  appears  negligible in  patients 
treated  with  CMF  regimens,  provided  that 
cyclophosphamide is given at standard dose.
Anthracyclines. The latency period between exposure 
to anthracyclines and the onset of leukemia is usually 
about  2  years,  and  generally  there  is  no  previous 
myelodysplastic phase (Table 2). In order to assess the 
risk of developing AML and MDS after exposure to 
epirubicin-based regimen, Praga et  al  reviewed 7110 
patients treated with epirubicin and cyclophosphamide 
in 19 randomized clinical trials in 2005. At a median 
follow up of eight years the cumulative probability of 
AML or MDS was 0.55%; however the risk increased 
in  relation  to  the  cumulative  doses  of  both  agents, 
ranging between 0.37% in patients received standard 
regimen  and  4.97%  for  those  treated  with  higher 
doses.
37 Similar  results  were  obtained  with 
doxorubicin-based  regimen.  In  a  large  French  case-
control  study,  the  risk  of  t-AML/MDS  in  women 
treated  for  BC  was  higher  in  those  who  received 
mitoxantrone-based chemotherapy than in those given 
anthracyclines.
38 Smith  et  al  performed  a  combined 
analysis  of  six  adjuvant  studies  conducted  by  the 
National Surgical Adjuvant Breast and Bowel Project 
group using regimens containing both doxorubicin and 
cyclophosphamide, and reported a 5-year incidence of 
AML ranging from 0.3% to 1.2%, with an increased 
risk  for  greater  dose  intensity.
39 The importance  of 
dose  intensity  was  also  confirmed  with  the  “intense 
dose-dense”  regimen  epirubicin,  paclitaxel  and 
cyclophosphamide every 2 weeks, which proved more 
effective  than  standard  schedule 
epirubicin/cyclophosphamide and improved event-free 
and overall survivals, but was also more toxic with four 
cases (0.6% of patients) of t-AML/MDS.
26
Antineoplastic  activity  of  taxanes  appears  to  be 
related  to  their  ability  to  promote  microtubular 
assembly and to  inhibit microtubular disassembly. A
SEER database analysis did not document an increased 
risk of secondary malignancies with these drugs.
23 A 7-
year  follow-up  of  a  trial  comparing 
doxorubicin/cyclophosphamide  (AC)  versus
docetaxel/cyclophosphamide (TC)  in  early  BC, 
reported  no  secondary  leukemia  in  the  TC  arm,Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
Table 2. Risk of therapy-related myeloid neoplasms in breast cancer patients receiving adjuvant chemotherapy with anthracyclines.
Reference Breast cancer 
patients (n) Therapy t-MN (n) Cumulative risk (%)
Bernard-Marty et al, 2002 [34] 267 Epirubicin-based regimens 3 0.9 (at 5 y)
Smith et al, 2003 [39] 6018
2545
Doxorubicin + CTX
Doxorubicin + CTX + G-CSF
21
22
0.12 (at 8 y)
0.86 (at 8 y)
Praga et al, 2005 [37] 7110 Epirubicin-based regimens 28 0.55 (at 8 y)
Campone et al, 2005 [35] 3653 Epirubicin-based regimens 8 0.34 (at 9 y)
Ejlertsen B et al, 2007 [24] 584 CEF 1 nr
Hershman et al, 2007 [40] 1569 Doxorubicin-based regimens 18 1.14
Patt et al, 2007 [23] 5213 Anthracycline-based regimens nr 1.53 (at 10 y)
Burnell et al, 2010 [28] 2104 Antracycline-based regimens 8 nr
CTX: cyclophosphamide; CEF: cyclophosphamide, epirubicin and fluorouracil; nr: not reported.
compared to two cases in 510 patients (0.4%) in the 
AC arm.
25
Role  of  Granulocyte  Colony-Stimulating  Factors 
(G-CSF)  and  Radiotherapy.  Recently,  increasing 
numbers of women receiving adjuvant chemotherapy 
for  BC  have  also  received  granulocyte  stimulating 
factors to reduce the myelosuppressive effects of dose-
intense  chemotherapy. In vitro data suggest that G-
CSF  may  increase  the  risk  of  AML/MDS,  but  its 
leukemogenic effect is still debated. An analysis of the 
SEER-medicare  population-based  database  including
5510  women  with  BC  treated  with  adjuvant 
chemotherapy,  found  that  the  addition  of  G-CSF  is 
associated with a doubling of the  risk of subsequent 
AML  or  MDS  when  compared  with  chemotherapy 
alone, even if the absolute risk is low.
40 In the analysis 
of six trials described by Smith et al and mentioned 
above, the incidence of therapy-related leukemia was 
sharply  elevated  in  patients  treated  with  intensified 
regimens  that  required  G-CSF  support  (relative  risk 
6.16, p=0.0001).
39 On the other hand, Patt et al did not 
find an increased risk for AML in elderly (>65 years) 
BC patients, who received G-CSF during the first years 
after diagnosis as part of adjuvant therapy.
23 Similarly, 
in the Cancer and Leukemia Group B 9741 phase III 
trial,  patients  received  dose-dense  regimens  plus 
filgrastim  support,  but  had  no  increased  risk  of 
developing AML or MDS compared to those treated 
with  the  same  regimen  at  conventional  schedule 
without  G-CSF.
27 Finally,  a  systematic review  of  25 
randomized  clinical  trials  was  recently  conducted  to 
evaluate the risk of AML or MDS in patients receiving 
chemotherapy for solid malignancies and lymphomas 
with or without the addition of G-CSF. At a median 
follow up of 54 months, the estimated relative risk for 
AML/MDS with G-CSF-supported chemotherapy was 
1.92,  with  an  estimate  absolute  increase  in  risk  of 
0.4%;
41 however,  although  this  increased  risk,  these 
data  cannot  distinguish  between  the  potential  causal
effects as a result of the growth factor and of dose-
intensified systemic chemotherapy, so that the potential
Table 3. Risk of therapy-related myeloid neoplasms in breast cancer patients receiving radiotherapy.
Reference Breast cancer 
patients (n) Therapy t-MN
(n) Cumulative risk (%)
Renella et al, 2006 [33] 2292
1119
Radiotherapy alone
Radiotherapy + chemotherapy
7
2
1.9
1.7
Howard et al, 2007 [4] 99275 Radiotherapy alone 221 0.22 (at 10 y)
Hershman et al, 2007 [40] 2837 Radiotherapy alone 38 1.33
Schaapveld et al, 2008 [5] 31000 Radiotherapy alone 13 1.28 (at 10 y)
Martin et al, 2009 [3] 420076 Radiotherapy +/- chemotherapy 450
0.91 (at 5 y) for range 15-49 years;
1.14 (at 5 y) for range 50-64 years;
1.76 (at 5 y) for >65 years
Zhang et al, 2011 [41]
1779
553
293
25
2650
Radiotherapy alone
Radio- + hormonal therapy
Radio- + chemotherapy
Radio- + hormonal+chemotherapy
Total
7 6.67 (at 4.5 y)Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
toxicities of G-CSF needs further study. 
Radiotherapy  may  also  play  a  significant  role 
(Table 3). A cohort study analyzing clinical records of 
BC patients with the aim of evaluating the long-term 
effect  of  radiotherapy  on  the  risk  of  second  cancers 
reported a total  of 387 malignancies (7.3%) in  5248 
women,  with  eight  patients  developing  leukemia 
(0.15%), seven in the group treated with radiotherapy,
versus one  case  only  in  the  group  not  receiving 
radiotherapy.  The  relative  risk  adjusted  for 
chemotherapy and hormone treatment was 6.67 (95% 
CI 0.76-58.00) and the median time from exposure was 
4.5 years, with the suggestion of a raised incidence of 
leukemia  within  the  first  two  or  more  years  after 
radiotherapy.
42 Similarly, in a previous study, the risk 
of developing AML resulted four-fold increased with 
the use of radiotherapy (HR 4, 95% CI 1.4-11.8) and 
by  seven folds when  radiotherapy  was  combined  to 
chemotherapy (HR 7.2, 95% CI 1.4-36.3).
33
Summary and Final Remarks.
In BC survivors, there is a small but significant 
and  increasing  number  of  secondary  myeloid 
neoplasms  after  adjuvant  chemotherapy, 
particularly after treatment with alkylating agents
and/or topoisomerase II inhibitors, that lead to two 
distinctly and different forms of t-MN.  
The  risk  of  leukemia  appears  very  low  if  the 
cumulative  dose  of  anthracyclines  and 
cyclophosphamide is not very high. Clinical trials 
attempting to improve therapeutic benefit by dose 
escalation need to take into account the increased 
risk  for  leukemia,  when  assessing  potential 
benefits and risks. 
The  incidence  of  t-MN  appears  to  be  also 
increased in patients treated for BC with surgery 
alone, and these cases are not “therapy-related”.
Thus, t-MN may be part of a cancer-risk syndrome 
involving  BC,  and  possibly  a  general  cancer 
susceptibility. 
A  raised  risk  of  t-MN  is  associated  with 
radiotherapy, particularly for women treated after 
the menopause. 
The concurrent use of G-CSFs as supportive care 
in  order  to  deliver  intensive  adjuvant 
chemotherapy could further enhance this risk, so 
that their use should be limited to the settings with 
available strong evidence. 
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